Erytech Pharma Goes Public In France with $21M IPO

Moran, Nuala
May 2013
BioWorld Today;5/14/2013, Vol. 24 Issue 92, p1
The article reports that shares in Erytech Pharma SA began trading in Paris, France after an initial public offering that exceeded 15 million euros, raising 16.7 million euros. This France-based company added 11 million euros, mainly through conversion of bonds, providing enough funds to get the lead program Graspa, used in the treatment of acute Lymphoblastic Leukemia, approved in Europe. The funds can also start a U.S. Phase 1b trial of Graspa.


Related Articles

  • Market watch: Upcoming market catalysts in Q1 2013. Inui, Edny // Nature Reviews Drug Discovery;Jan2013, Vol. 12 Issue 1, p12 

    The article focuses decision to approve ponatinib as treatment to chronic myeloid leukaemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) which is considered as one of the market catalysts in the first quarter of 2013. It says that the U.S. Food and Drug...

  • CAR-T cell therapy gets breakthrough status.  // Nature Biotechnology;Sep2014, Vol. 32 Issue 9, p851 

    The article offers information on the approval for the University of Pennsylvania's CTL019 chimeric antigen receptor T (CAR-T) cell?based immunotherapy, by the U.S. Food and Drug Administration (FDA) in July 2014 for the treatment of acute lymphoblastic leukemia.

  • After Resubmitting BLA, Dyax Adding $15M in Public Offering. Boggs, Jennifer // BioWorld Today;6/26/2009, Vol. 20 Issue 122, p1 

    This article reports on a public offering launched by Dyax Corp. after the U.S. Food & Drug Administration (FDA) accepted the firm's resubmitted application for hereditary angioedema drug DX-88. The company is selling about 7.4 million shares for $2.02 each. It plans to use the proceeds to...

  • HGS Bulks up with $415M Public Offering.  // Bioworld Week;12/7/2009, Vol. 17 Issue 49, p5 

    The article informs that Human Genome Sciences Inc. (HGS) is planning to raise finance through public offering of a million shares after the submission of its biologics license application for its drug Zalbin used in the treatment of hepatitis C. The company based in Rockville, Maryland is...

  • Financings Roundup.  // BioWorld Today;7/16/2007, Vol. 18 Issue 136, p4 

    This section offers news about financing deals. Nuvo Research Inc. has successfully raised some funds via a public offering. A nonbrokered Series B round of funding was closed by NexGenix Pharmaceuticals Holdings Inc. to progress offshore clinical trials of its lead compound in dermal...

  • Pharmasset Prices IPO Lower Than Expected To Raise $45M. Boggs, Jennifer // BioWorld Today;4/30/2007, Vol. 18 Issue 83, p1 

    The article reports that Pharmasset Inc. has set a $9 per share price for its initial public offering (IPO). The company aims to raise $45 million from the IPO. Previously, the company priced its shares between $12 and $14, but reduced it to $9 in relation to the Phase II program for clevudine....

  • Biotech Sector Perks Up, But is it Enough to be Giddy? Robbins-Roth, Cynthia // BioWorld Today;7/6/2011, Vol. 22 Issue 129, p1 

    The article explores venture capital trends in the biotechnology sector in 2011. During the first quarter of the year, four biotechnology initial public offerings (IPOs) were completed. It notes a 37% increase in the total amount of dollars raised in the sector by the end of the second quarter....

  • 'Regado' Nuff Money Now? IPO Brings $43M to Push Phase III. Osborne, Randy // BioWorld Today;8/23/2013, Vol. 24 Issue 162, p1 

    The article reports on the initial public offering (IPO) launched by biopharmaceutical firm Regado Biosciences Inc. in 2013. The IPO will enable the firm to proceed with the Phase III trial of REG1, an anticoagulation system. As of August 22, 2013, Regado shares rose by 17.5% to 4.70 dollars....

  • Chelsea Pads Cash Position.  // BioWorld Today;11/5/2007, Vol. 18 Issue 215, p5 

    The article reports that Chelsea Therapeutics International Inc. has entered into a direct offering of 7.4 million shares of common stock in 2007. Proceeds of the deal will be used for research, clinical trials, general working capital and potential licensing or acquisitions. The Phase III trial...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics